Organon & Co. (NYSE:OGN) Reaches New 1-Year Low – What’s Next?

Organon & Co. (NYSE:OGN) reached a new 52-week low during trading on Friday . The stock traded as low as $13.25 and last traded at $13.18, with a volume of 785212 shares traded. The stock had previously closed at $14.45.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on OGN. Morgan Stanley decreased their target price on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, February 14th. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. Finally, Barclays dropped their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $20.80.

Organon & Co. Stock Down 9.8 %

The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The stock has a market cap of $3.36 billion, a P/E ratio of 3.91, a PEG ratio of 0.90 and a beta of 0.73. The company’s 50 day moving average price is $15.16 and its two-hundred day moving average price is $16.02.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The business had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Equities analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were issued a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 8.59%. The ex-dividend date was Monday, February 24th. Organon & Co.’s dividend payout ratio is presently 33.63%.

Institutional Investors Weigh In On Organon & Co.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Organon & Co. by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company’s stock worth $453,593,000 after purchasing an additional 218,165 shares during the period. Pacer Advisors Inc. boosted its holdings in Organon & Co. by 94,482.1% in the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock worth $166,391,000 after buying an additional 11,140,388 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in Organon & Co. by 1.4% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 9,895,067 shares of the company’s stock worth $147,634,000 after buying an additional 136,760 shares during the period. LSV Asset Management increased its stake in Organon & Co. by 0.4% in the 4th quarter. LSV Asset Management now owns 7,525,076 shares of the company’s stock worth $112,274,000 after buying an additional 30,557 shares in the last quarter. Finally, Deprince Race & Zollo Inc. raised its holdings in Organon & Co. by 7.0% during the fourth quarter. Deprince Race & Zollo Inc. now owns 4,729,258 shares of the company’s stock valued at $70,561,000 after acquiring an additional 308,267 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.